48 research outputs found

    Species Review of Amphibian Extinction Risks in Madagascar: Conclusions from the Global Amphibian Assessment

    Full text link
    We assessed the extinction risks of Malagasy amphibians by evaluating their distribution, occurrence in protected areas, population trends, habitat quality, and prevalence in commercial trade. We estimated and mapped the distribution of each of the 220 described Malagasy species and applied, for the first time, the IUCN Red List categories and criteria to all species described at the time of the assessment. Nine species were categorized as critically endangered, 21 as endangered, and 25 as vulnerable. The most threatened species occur on the High Plateau and/or have been subjected to overcollection for the pet trade, but restricted extent of occurrence and ongoing habitat destruction were identified as the most important factors influencing extinction threats. The two areas with the majority of threatened species were the northern Tsaratanana-Marojejy-Masoala highlands and the southeastern Anosy Mountains. The current system of protected areas includes 82% of the threatened amphibian species. Of the critically endangered species, 6 did not occur in any protected area. For conservation of these species we recommend the creation of a reserve for the species of the Mantella aurantiaca group, the inclusion of two Scaphiophryne species in the Convention on the International Trade in Endangered Species Appendix II, and the suspension of commercial collecting for Mantella cowani . Field surveys during the last 15 years reveal no pervasive extinction of Malagasy amphibians resulting from disease or other agents, as has been reported in some other areas of the world.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/75394/1/j.1523-1739.2005.00249.x.pd

    The elephant in the room: Madagascar's rosewood stocks and stockpiles

    No full text
    To prevent the illegal trade in wild species, stock management is critical given stocks function as a buffer to supply chains during lean periods or as a mechanism for market speculation. The Madagascar government with backing by the World Bank recently promoted the sale of confiscated rosewood to reach a zero‐stocks situation. To better assess options, we contrast the risks and rewards of four stock management options. Stock destruction broadcasts a potent conservation message, but provides little economic benefit. National trade can be beneficial to local socioeconomic development goals, but can lead to laundering of illegal products. International trade is fraught with risks related to illegal trade and is perceived to achieve the least related to forest and socioeconomic indicators. Lastly, banking stocks act to postpone decisions. No management option ensures a sustainable solution, but critical analyses allow better insight to the strengths and weaknesses of the available approaches.ISSN:1755-263

    Facteurs de risque d’asthĂ©nie en cours de la radiothĂ©rapie des cancers du sein et de la prostate

    No full text
    International audienceObjectifs de l’étude Une asthĂ©nie est frĂ©quemment rapportĂ©e en cours de radiothĂ©rapie, le plus souvent sans Ă©tiologie Ă©vidente. L’objectif de ce travail Ă©tait de mettre en Ă©vidence les causes de l’asthĂ©nie ressentie par les patients en cours d’irradiation Ă  visĂ©e curative du sein ou de la prostate. MatĂ©riel et mĂ©thodes Une Ă©tude rĂ©trospective a Ă©tĂ© menĂ©e Ă  l’Institut de CancĂ©rologie Lucien Neuwirth chez les patients irradiĂ©s en intention curative durant l’annĂ©e 2015 (n = 806) pour un cancer du sein ou de la prostate. L’asthĂ©nie en cours de radiothĂ©rapie et la tolĂ©rance globale du traitement ont Ă©tĂ© Ă©valuĂ©es Ă  l’aide d’une Ă©chelle verbale simple (de 0/10 Ă  10/10). Les autres donnĂ©es (toxicitĂ©, distance par rapport au centre, temps de trajet quotidien, caractĂ©ristiques tumorales, caractĂ©ristiques du traitement de radiothĂ©rapie, traitement anticancĂ©reux antĂ©rieurs) Ă©taient collectĂ©es dans les dossiers mĂ©dicaux. RĂ©sultats Cinq cent patients ont Ă©tĂ© inclus dans l’étude. Au total, 86 % des patientes traitĂ©es pour un cancer du sein ont ressenti de l’asthĂ©nie, avec un score mĂ©dian de 5/10. Au total, 54 % des patients traitĂ©s pour un cancer de la prostate ont ressenti de l’asthĂ©nie, avec un score mĂ©dian de 2/10. Des corrĂ©lations ont Ă©tĂ© mises en Ă©vidence seulement en analyse unifactorielle dans le groupe des irradiations prostatiques, entre l’asthĂ©nie et la tolĂ©rance globale, et entre l’asthĂ©nie et le T de la classification TNM. Conclusions L’asthĂ©nie en cours de radiothĂ©rapie Ă©tait une plainte frĂ©quente. Les facteurs habituellement avancĂ©s pour l’expliquer (trajets itĂ©ratifs, chimiothĂ©rapie antĂ©rieure, etc.) n’étaient pas corrĂ©lĂ©s avec l’asthĂ©nie ressentie par le patient au cours d’irradiatio
    corecore